Michael J. Campa

Michael J. Campa is one of the scientific co-founders of Grid Therapeutics and has worked closely with Dr. Patz for 25 years. He developed or co-developed techniques for identifying potential biomarkers using MALDI-TOF MS, phage display, and immunological techniques. Much of the past 15 years has focused on the immunological response to cancer and the identification of antigens recognized by patient-expressed autoantibodies. It was this approach that led directly to the discovery of the autoantibody that has become Grid’s lead asset and the development of a new discovery platform for anti-cancer antibodies.

Before coming to Duke, Mike worked with Kwen-Jen Chang at Burroughs Wellcome Co. in Research Triangle Park, NC where he explored the roles of the Ras protein family in cancer. Dr. Campa received his PhD in biochemistry and molecular biology from the University of Florida in Gainesville, under the direction of Michael Kilberg.